Pharma channel feed – Endpoints News

Pharma channel feed

Braeburn petitions FDA to revoke Sublocade orphan designation

7 years ago

Regeneron, Alnylam spell out a research alliance that could run beyond a decade, with billions built in for success

7 years ago

In combat mode, Indivior hunkers down for a war with DoJ over multibillion-dollar fraud charges

7 years ago

FDA, Brigham and Women’s to test if RWE is ripe now for replacing clinical drug trials

7 years ago

Chinese player joins a growing group of biotechs buying into Synaffix's ADC linker tech

7 years ago

Compared to avoidance, Aimmune's peanut allergy treatment an improvement over DBV's product — ICER

7 years ago

As public furor mounts, Sanofi makes deep cuts to US insulin prices in savings program

7 years ago

Once spurned, Amgen wins the FDA over with its bone-building osteoporosis drug Evenity

7 years ago

Two Republican lawmakers feel 'obliged' to warn drugmakers that Democrat colleague Cummings is purportedly out to deflate their stock prices

7 years ago

BeiGene lines up a next-gen CTLA-4 to complement its PD-1 pillar in new deal worth up to $270M

7 years ago

PhaseBio touts 'breakthrough' badge for bloodthinner reversal agent licensed from AstraZeneca, shares leap

7 years ago

Battered and out of options, Histogenics turns to eye drug developer Ocugen for reverse merger

7 years ago

Celgene, Acceleron submit FDA application for billed blockbuster luspatercept — will they get priority review?

7 years ago

Going gangbusters: The top 20 biotech platform deals by upfront cash

7 years ago

At a cool $1B-plus in upfront, equity and early-stage cash, Regeneron ties a blockbuster R&D partnership knot with RNAi leader Alnylam

7 years ago

Jazz, Lundbeck and Alexion pay $122M+ to resolve DoJ claims of using charities as 'conduits' to stimulate use of their drugs

7 years ago

Billions on the line, Novartis and Amgen exchange broadsides as Aimovig partnership erupts into a legal war

7 years ago

Already missing FDA's vocal commish? Scott Gottlieb will keep chiming in on drug pricing in new role

7 years ago

Vivek Ramaswamy launches yet another Vant, this time in Asia with a TCR-focused Medigene partnership

7 years ago

To be cost-effective, Biogen should slash Spinraza price, and Novartis cannot justify a $4M-$5M price tag for Zolgensma — ICER

7 years ago

Watch out Eli Lilly, AbbVie and Biogen: 7 new blockbusters are on their way to shake things up

7 years ago

After falling short on prelim OS data, EMA tells Aveo it wants to see something better on its long suffering tivo this summer — or else

7 years ago

Editas and BlueRock join forces — and platform technologies — on a new wave of engineered cell therapies

7 years ago

Atlas wraps Arteaus story with $260M royalty sale as Emgality sales inches upward

7 years ago

First page Previous page 275 276 277278279 280 281 Next page Last page